Narmac, biotech investing is one of the riskiest asset classes and the time frame from  drug concept ,trials to drug approval can easily take up to 20  years ,  so at 10 years now  were getting closer to the finish line lol   Plus Zenith has a 4 or major BP clinical partnerships and collaboations and with several very reputable institutions NIH, etc etc so they see Zen 3694 as something possibly valuable to their pipeline , could be sooner than later .....   take a gander of this articel if you have a few minutes . I do get your frustration at management on both teams , DM is pathetic and needs to be replaced IMO

https://www.forbes.com/sites/brucebooth/2019/05/20/biotech-startups-and-the-hard-truth-of-innovation/?sh=6de90043867b